Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell) in Population Aged 18 Years and Above

NCT05293548 is registered in ClinicalTrials.gov with National Vaccine and Serum Institute, China as lead sponsor.

NCT NCT05293548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05293548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell) in Population Aged 18 Years and Above
Lead sponsor
National Vaccine and Serum Institute, China
Phase
Phase 2
Overall status
Unknown status
Start date
May 25, 2022
Completion date
August 31, 2023
Enrollment
516 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19